183 related articles for article (PubMed ID: 2300353)
1. Preoperative serum tumor-associated antigen levels in women with pelvic masses.
Soper JT; Hunter VJ; Daly L; Tanner M; Creasman WT; Bast RC
Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353
[TBL] [Abstract][Full Text] [Related]
2. Serum CA 125 levels in preoperative evaluation of pelvic masses.
Vasilev SA; Schlaerth JB; Campeau J; Morrow CP
Obstet Gynecol; 1988 May; 71(5):751-6. PubMed ID: 3162763
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
Chen DX; Schwartz PE; Li XG; Yang Z
Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic significance of preoperative determination of CA-125 serum levels in the differentiation of malignant and benign pelvic masses].
Durdević S; Segedi D; Vejnović T; Radeka G
Med Pregl; 1992; 45(7-8):262-5. PubMed ID: 1344453
[TBL] [Abstract][Full Text] [Related]
5. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
Chen DX; Schwartz PE; Li FQ
Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses.
O'Connell GJ; Ryan E; Murphy KJ; Prefontaine M
Obstet Gynecol; 1987 Dec; 70(6):930-2. PubMed ID: 3479735
[TBL] [Abstract][Full Text] [Related]
7. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
[TBL] [Abstract][Full Text] [Related]
9. [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker].
Zeimet AG; Guadagni F; Marth C; Amato T; Müller-Holzner E; Huter O; Daxenbichler G; Dapunt O
Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):195-9. PubMed ID: 7789707
[TBL] [Abstract][Full Text] [Related]
10. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
[TBL] [Abstract][Full Text] [Related]
11. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
[TBL] [Abstract][Full Text] [Related]
12. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility?
Roman LD; Muderspach LI; Burnett AF; Morrow CP
J Reprod Med; 1998 May; 43(5):403-7. PubMed ID: 9610461
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses.
Patsner B; Mann WJ; Chalas E
Obstet Gynecol; 1988 Jun; 71(6 Pt 1):949-50. PubMed ID: 3163416
[No Abstract] [Full Text] [Related]
14. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
Jacobs IJ; Oram DH; Bast RC
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
16. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.
Plante M; Wong GY; Nisselbaum JS; Almadrones L; Hoskins WJ; Rubin SC
Obstet Gynecol; 1993 Jun; 81(6):989-92. PubMed ID: 8497368
[TBL] [Abstract][Full Text] [Related]
17. CA 195: a new monoclonal antibody-defined Lea blood group-related tumor marker in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Prontera C; Moretti L; Pellagatta L; Bianchi R; Fioretti P
J Nucl Biol Med (1991); 1991; 35(1):33-7. PubMed ID: 1657201
[TBL] [Abstract][Full Text] [Related]
18. The role of the CA 125 assay in the management of ovarian cancer.
Niloff JM
Oncology (Williston Park); 1988 Aug; 2(8):67-76. PubMed ID: 3275060
[TBL] [Abstract][Full Text] [Related]
19. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.
Zhang Z; Barnhill SD; Zhang H; Xu F; Yu Y; Jacobs I; Woolas RP; Berchuck A; Madyastha KR; Bast RC
Gynecol Oncol; 1999 Apr; 73(1):56-61. PubMed ID: 10094881
[TBL] [Abstract][Full Text] [Related]
20. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data.
Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
J Nucl Med Allied Sci; 1989; 33(1):32-6. PubMed ID: 2746365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]